Effect of different patient peak arrivals on an Emergency Department via discrete event simulation

Autor: Fava, G., Giovannelli, T., Messedaglia, M., Roma, M.

Emergency Departments (EDs) overcrowding is a well recognized worldwide phenomenon. The consequences range from long waiting times for visits and treatment of patients up to life-threatening health conditions. The international community is devoting

Externí odkaz: http://arxiv.org/abs/2101.12432

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

Autor: Luxi N., Giovanazzi A., Capuano A., Crisafulli S., Cutroneo P. M., Fantini M. P., Ferrajolo C., Moretti U., Poluzzi E., Raschi E., Ravaldi C., Reno C., Tuccori M., Vannacci A., Zanoni G., Trifiro G., Petrelli G., Girotti S., Arzenton E., Magro L., Lora R., Bellantuono D., Sabaini A., Firenze A., Zodda D., Guidotti F., Zappone M., Alagna B., Spina E., Minore C., Costantino C., Conforto A., Vitale F., Morreale I., Marsala L., Farinella D., Bavetta S., Sapigni E., Potenza A. M., Podetti D., Nikitina V., Ricciardelli R., Mogheiseh N., Croce S., Paltrinieri B., Castellani S., Sangiorgi E., Selleri M., Lucchesi S., Catucci G., Savini D., Sacripanti C., Faccioli M., Romio M. S., Rossi L., Radici S., Negri G., Fares L., Ajolfi C., Fadda A., Chiarello A., Pieraccini F., Pappalardo F., Bonaiuti R., Lombardi N., Crescioli G., Tessari R., Zandona E., Marchiori F., Chiamulera C., Senna G., Crivellaro M. A., Cancian M., Venturini F., Ferri M., Leonardi L., Orzetti S., Caccin E., Baldo P., Rafaniello C., Pagliaro C., Mercaldo M., Fucile A., di Giorgio A., Tari M., Manna S., Farina G., Di Mauro C., De Carlo I., Senesi I., Pileggi C., Palleria C., Gallelli L., De Sarro G., Trabace L., Morgese M., Schiavone S., Tucci P., Bove M., Lapi F., Cricelli C., Racagni G., Tonolo S., Leopardi E., Fava G., Giuffrida S., Amato V., Gambera M., Montresor V.

Publikováno v: Drug Safety

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (prev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcbb1fe9555478fb36e1a7ddd4735ab1
http://hdl.handle.net/11585/851640

Per un’ontologia della soglia: note su natura e cultura in Philippe Descola

Autor: Fava, G.

Publikováno v: Aretè

The aim of this paper is to clarify the philosophical implications of the role that the conceptual dichotomy between nature and culture detains in Philippe Descola’s anthropological works. Descola has shown that both the concept of nature and cultu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1874::45542c15627cc50e0bd693a052d52561
https://hdl.handle.net/21.11116/0000-000B-4AC4-521.11116/0000-000B-4AC6-3

Encouraging Academic Competition in Europe

Autor: Fava, G. A., Breno, E., Guardabasso, V., Stefanelli, M.

Publikováno v: Science, 2002 Nov . 298(5599), 1715-1716.

Externí odkaz: https://www.jstor.org/stable/3832983

The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes

Autor: Carrai, P, Morelli, C, Cordone, G, Romano, A, Tamé, M, Lionetti, R, Pietrosi, G, Lenci, I, Piai, G, Russo, F, Coppola, C, Melazzini, M, Montilla, S, Pani, L, Petraglia, S, Russo, P, Trotta, M, Martini, S, Toniutto, P, the ITACOPS study group, Bandiera, F, Bhoori, S, Brillanti, S, Burra, P, Corsale, S, De Luca, A, Fagiuoli, S, Fattovich, G, Fava, G, Felder, M, Forte, P, Galeota-Lanza, A, Gitto, S, Grieco, A, Grossi, P, Ialungo, A, Iemmolo, R, Loiacono, L, Mangia, A, Merli, M, Piacentini, A, Pellicelli, A, Rigamonti, C, Gabriella, V, Zignego, A. L.

Direct antivirals are available for treating recurrent hepatitis C (RHC). This study reported outcomes of 424 patients with METAVIR F3–F4 RHC who were treated for 24 weeks with sofosbuvir/ribavirin and followed for 12 weeks within the Italian sofos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1839cb579130db448680eebf36b176
http://hdl.handle.net/11573/1064914